• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYInsights
  • MYBoard
  • Strategy & Consulting
Select Page

Beyond the Diagnosis: A Stage-by-Stage Guide to Multiple Myeloma Treatment

by MM360 Staff | Sep 19, 2025 | Uncategorized

Source: CureToday articles Diagnosed with multiple myeloma? Our guide explains each stage and treatment, helping you engage confidently with your care team. Read More

Looking Back on the Shock of a Multiple Myeloma Diagnosis

by MM360 Staff | Sep 19, 2025 | Uncategorized

Source: CureToday articles What is the first emotion that comes to mind about your cancer journey? For me, the strong emotion that I choose is shock! Read More

Subcutaneous Darzalex Faspro Extends PFS in Smoldering Myeloma

by MM360 Staff | Sep 7, 2025 | Uncategorized

Source: CureToday articles Data from the AQUILA study support the use of fixed-duration subcutaneous Darzalex Faspro as an early treatment option in high-risk smoldering myeloma. Read More

What Does Multiple Myeloma Mean?

by MM360 Staff | Aug 23, 2025 | Uncategorized

Source: CureToday articles Multiple myeloma is a chronic blood cancer affecting plasma cells, but with today’s treatments many patients can manage symptoms and live fulfilling lives. Read More

FDA Update: Darzalex Faspro Not Approved for Multiple Myeloma

by MM360 Staff | Aug 21, 2025 | Uncategorized

Source: CureToday articles The FDA declined approval of Darzalex Faspro for newly diagnosed, transplant-ineligible multiple myeloma in its current form. Read More

Why New Patients With Multiple Myeloma ‘Can Expect Long, Healthy Lives’

by MM360 Staff | Aug 15, 2025 | Uncategorized

Source: CureToday articles Dr. Jim Omel, who was diagnosed with multiple myeloma in 1997, explained how the treatment landscape has changed over nearly 30 years. Read More
« Older Entries
Next Entries »

Recent Content

  • Canada agency backs coverage of new ovarian cancer drug
  • (no title)
  • Caribou’s CB-011 may be effective, safe for hard-to-treat myeloma
  • Therapy wins rare pediatric disease designation for hard-to-treat glioma
  • November shines a spotlight on pancreatic cancer awareness
  • Cero seeking more safety, dosing data on T-cell therapy for AML
  • (no title)
  • Efficacy of novel therapies for refractory and relapsed multiple myeloma in China: A scoping systematic review
  • Cytomegalovirus reactivation during treatment with bispecific antibodies for relapsed/refractory multiple myeloma
  • Cytomegalovirus reactivation during treatment with bispecific antibodies for relapsed/refractory multiple myeloma
  • Facebook
  • X
  • Instagram
©2016-2025 MYELOMA360 & Connect BioMed
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT